Stock URGN UROGEN PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
13.24 USD +3.04% Intraday chart for UroGen Pharma Ltd. +0.15% -11.73%
May. 14 Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating MT
May. 13 Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
BU
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
BU
UroGen Pharma to Participate at Upcoming Investor Conferences
BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
AQ
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
AQ
UroGen Pharma Ltd. - New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
AQ
UroGen Pharma Ltd. - New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
AQ
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
BU
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
BU
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
BU
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
BU
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS
AQ
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
BU
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
BU
UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
AQ
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
BU
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. URGN Stock
  4. News UroGen Pharma Ltd.
  5. Press Releases